Learn more about BioRestorative’s current ongoing Phase 2 clinical trial.
Search for study ID number: NCT04042844 at clinicaltrials.gov.
Regenerative Biology for Longevity and Healthier Lives
Advancing stem cell science to address unmet needs in chronic pain and metabolic disorders
Current Trials
BRTX-100: Phase 2 Clinical Trial
A Single Dose of BRTX-100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Recruiting
ABOUT US
BioRestorative Therapies
Developing therapeutic products using advanced cell and tissue protocols, primarily involving adult stem cells. Our clinical programs address critical healthcare needs, including degenerative disc disease and metabolic disorders, while our BioCosmeceutical platform explores innovative applications in aesthetic medicine.
NASDAQ:BRTX
Our Products
DEVELOPMENT
Bone marrow derived mesenchymal stem cells
Brown adipose derived stem cells
COMMERCIAL
Secretome (novel exosome, growth factor/cytokine) biologics based technology for cosmetic applications
Latest News
Press Releases
Explore BioRestorative’s latest press releases
Latest Presentation
View our most recent company overview and investment highlights
Email Alerts
Sign up today and receive company updates straight to your inbox